Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed GlobeNewswire November 18, 2025 The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an […]